Clinical Trials Logo

Gastroesophageal Cancer clinical trials

View clinical trials related to Gastroesophageal Cancer.

Filter by:

NCT ID: NCT06283238 Not yet recruiting - Clinical trials for GastroEsophageal Cancer

Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)

Start date: April 25, 2024
Phase:
Study type: Observational

The goal of this observational study is to examine genetic changes that may contribute to immunotherapy resistance in gastroesophageal cancer. This information can potentially lead to the identification of new immunotherapeutic targets as well as improve the ability to identify those patients more likely to respond to immunotherapy. This study does not include any treatment or investigational drugs. Participants will be asked: - to enroll before beginning standard care of treatment for their cancer - for blood, archived tumor tissue, and fresh tumor tissue Researchers will compare participants who are not getting immunotherapy to identify potential differences in expression levels of a gene.

NCT ID: NCT06243757 Recruiting - Gastric Cancer Clinical Trials

A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers

Start date: January 8, 2024
Phase:
Study type: Observational

Participants will a diagnosis of gastroesophageal junction (GEJ) adenocarcinoma and will have either a minimally invasive proximal gastrectomy (MIPG) or a minimally invasive total gastrectomy (MITG) as part of their routine care. Participants with complete a questionnaire 1 month before the surgical procedure and then 1, 3, 6 and 12 months after the surgical procedure.

NCT ID: NCT06241469 Not yet recruiting - Gastric Cancer Clinical Trials

Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction,a Phase II Clinical Study

Start date: February 3, 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to find better protocal for adenocarcinoma of the gastric and gastroesophageal juncion. The main question is aim to answer is: 1. The efficacy and safety of PD-1 monoclonal antibody (Sintilimab) combined with nab-paclitaxel and S-1 in the first-line treatment of advanced gastric and gastroesophageal junction adenocarcinoma. Participants will be given PD-1 monoclonal antibody, nab-paclitaxel and tegio.

NCT ID: NCT06239194 Not yet recruiting - Breast Cancer Clinical Trials

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Start date: May 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

NCT ID: NCT06171789 Recruiting - Ovarian Cancer Clinical Trials

PRO1107 in Patients With Advanced Solid Tumors

Start date: January 29, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, PK, and antitumor activity of PRO1107 in patients with advanced solid tumors. This study consists of 2 parts, Part A: dose escalation and dose level expansion, and Part B: tumor specific expansion.

NCT ID: NCT06138223 Active, not recruiting - Clinical trials for GastroEsophageal Cancer

The Effect of exeRcise And Diet on Quality of Life in Patients With Incurable Cancer of Esophagus and Stomach (RADICES)

RADICES
Start date: October 1, 2023
Phase: N/A
Study type: Interventional

The survival of patients with incurable gastroesophageal cancer can extend over a year with anticancer therapy. However, the number of patients with deteriorating quality of life in this patient group steadily decreases over time during the treatment. Potentially reversible causes related to deterioration of quality of life are diminished muscle mass, physical capacity and nutritional status. Therefore, interventions that can target these in order to maintain or improve quality of life are urgently needed. However, it is yet unknown whether improvement of physical capacity and nutritional status improves quality of life in patients with incurable gastroesophageal adenocarcinoma after failure of first-line treatment. Since these patients are in a precarious situation, the benefits and harms of a combined exercise and nutritional intervention should be carefully evaluated.Therefore this study investigates the effect of a combined exercise and nutrition intervention compared to usual care on quality of life in incurable GAC patients after progression upon first-line treatment. A total of 196 patients with metastasized gastroesophageal cancer will be recruited and randomly allocated 1:1 to standard care or standard care plus a combined exercise and nutritional intervention.

NCT ID: NCT06109467 Recruiting - Gastric Cancer Clinical Trials

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Start date: January 12, 2024
Phase: Phase 2
Study type: Interventional

The purpose of the study is to test the effects, both good and bad, of the research study drug Neratinib in combination with Trastuzumab, Pembrolizumab and FOLFOX chemotherapy. This study will also look at the safety of Neratinib in combination with Trastuzumab, Pembrolizumab and FOLFOX in HER2 overexpressing Gastroesophageal cancers.

NCT ID: NCT06028737 Recruiting - Gastric Cancer Clinical Trials

Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer

OCTASUR
Start date: August 25, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The main goal of this study is to investigate the histopathological regression rate in patients with locally advanced gastric and gastroesophageal adenocarcinoma without previous treatment who will be prospectively randomized into two groups to undergo one of two chemotherapy regimens, followed by surgery: 1. 8 cycles of Total Neoadjuvant ChemoTherapy (TNT) with 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Docetaxel (FLOT) followed by surgery. 2. 4 cycles of Neoadjuvant FLOT chemotherapy scheme preoperatively and 4 adjuvant FLOT cycles postoperatively.

NCT ID: NCT05924789 Recruiting - Pancreatic Cancer Clinical Trials

Epidemiological Characteristics of Gastric and Pancreatic Cancers in Latin America

GASPAR
Start date: August 11, 2023
Phase:
Study type: Observational

Currently, there is no Brazilian or Latin American epidemiological data, such as clinical-pathological characteristics, standard treatments and outcomes of gastric cancer and pancreatic cancer in the region. The study aims to create a Latin American multicenter database to analyze epidemiological, clinical, and pathological data, treatments, outcomes, and biological information from patients with gastric and pancreatic cancer.

NCT ID: NCT05717998 Recruiting - Esophagus Cancer Clinical Trials

Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy

Start date: April 2, 2021
Phase:
Study type: Observational

This study assesses for early signs of damage to the heart following chest radiation therapy using both imaging (cardiac magnetic resonance imaging and cardiac positron emission tomography) and changes in blood biomarkers. This study determines if any changes in the heart muscle can be detected either during the course of radiation therapy or shortly thereafter using specialized imaging techniques or blood tests. Cardiac magnetic resonance imaging may be used to help provide information about changes in the heart structure and function following radiation therapy. Positron emission tomography looks at differences in how the heart takes up radioactive sugar which is injected into the vein to assess changes in heart function following radiation therapy. This study may help identify patients at risk of heart issues following radiation therapy to the chest and ultimately help in the development of more effective and safe treatments for cancer in the future.